Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Instagram Outage Disrupts Thousands of U.S. Users 
REDWOOD CITY, Calif., Aug. 02, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report second quarter 2017 financial results after market close on Wednesday, August 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | ||
| International | 720 634 2938 | |||
| Passcode | 60083694 | |||
| Live Webcast: | Codexis IR Website | |||
| The webcast will be archived for 30 days. | ||||
| Replay: | U.S. | 855 859 2056 | ||
| International | 404 537 3406 | |||
| Passcode | 60083694 | |||
| The replay will be available for 48 hours | ||||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
CONTACTS:
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
